We are live on
!
Find out more
O
OppenheimerFunds Portfolio holdings
AUM
$80.4B
1-Year Est. Return
15.1%
This Fund
S&P 500
This Quarter
Est. Return
+6.63%
1 Year Est. Return
+15.1%
3 Year Est. Return
+72.05%
5 Year Est. Return
+91.1%
10 Year Est. Return
–
AUM
$82.8B
AUM Growth
+$1.44B
(+1.8%)
Cap. Flow
-$2.02B
Cap. Flow
% of AUM
-2.43%
Top 10 Holdings %
Top 10 Hldgs %
16.17%
Holding
1,933
New
90
Increased
882
Reduced
857
Closed
96
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
eBay
EBAY
|
+$366M |
| 2 |
CarMax
KMX
|
+$273M |
| 3 |
O'Reilly Automotive
ORLY
|
+$240M |
| 4 |
Motorola Solutions
MSI
|
+$212M |
| 5 |
Alibaba
BABA
|
+$201M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$401M |
| 2 |
TechnipFMC
FTI
|
+$399M |
| 3 |
AutoZone
AZO
|
+$327M |
| 4 |
Cisco
CSCO
|
+$232M |
| 5 |
NetEase
NTES
|
+$181M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 15.41% |
| 2 | Consumer Discretionary | 14.11% |
| 3 | Energy | 13.48% |
| 4 | Healthcare | 12.91% |
| 5 | Technology | 11.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Jazz Pharmaceuticals
JAZZ
$15.9B
| $20.3M | 0.02% |
150,854
-58,116
| -28% | -$8.06M |
|
577
Halozyme
HALO
$9.72B
| $20.3M | 0.02% |
1,002,315
-178
| -0% | -$3.27K |
|
578
FerroAtlántica
GSM
$628M
| $20.2M | 0.02% |
+1,249,720
| New | +$19.4M |
|
579
Universal Health Services
UHS
$9.43B
| $20.2M | 0.02% |
178,552
+151,633
| +563% | +$16.2M |
|
580
Owens Corning
OC
$11.5B
| $20.2M | 0.02% |
220,074
+27,944
| +15% | +$2.35M |
|
581
MSCI
MSCI
$40B
| $20.2M | 0.02% |
159,515
+3,932
| +3% | +$491K |
|
|
RP
582
DELISTED
RealPage, Inc.
RP
| $20.2M | 0.02% |
455,000
+160,085
| +54% | +$6.99M |
|
583
TransUnion
TRU
$14.8B
| $20.1M | 0.02% |
366,518
-36,232
| -9% | -$1.93M |
|
584
MaxLinear
MXL
$6.49B
| $20.1M | 0.02% |
760,914
-12,310
| -2% | -$308K |
|
|
FCB
585
DELISTED
FCB Financial Holdings, Inc.
FCB
| $20.1M | 0.02% |
394,932
+18,121
| +5% | +$889K |
|
586
Oshkosh
OSK
$9.67B
| $19.9M | 0.02% |
219,441
+196,343
| +850% | +$17.2M |
|
587
Bio-Techne
TECH
$11.2B
| $19.9M | 0.02% |
613,080
+404
| +0.1% | +$12.8K |
|
|
CCLP
588
DELISTED
CSI Compressco LP
CCLP
| $19.8M | 0.02% |
3,627,135
+324,027
| +10% | +$1.69M |
|
|
SNMP
589
DELISTED
Evolve Transition Infrastructure LP
SNMP
| $19.8M | 0.02% |
59,414
-516
| -0.9% | -$174K |
|
590
Paycom
PAYC
$6.78B
| $19.8M | 0.02% |
246,229
-32,122
| -12% | -$2.57M |
|
591
Neogen
NEOG
$2.05B
| $19.7M | 0.02% |
852,885
+233,752
| +38% | +$7.08M |
|
592
HCA Healthcare
HCA
$84.8B
| $19.7M | 0.02% |
223,725
-71,239
| -24% | -$5.72M |
|
|
VISN
593
Vistance Networks Inc
VISN
$2.66B
| $19.6M | 0.02% |
518,258
+276,567
| +114% | +$9.64M |
|
594
IDEX
IEX
$16.5B
| $19.5M | 0.02% |
147,768
+3,593
| +2% | +$462K |
|
595
Rigel Pharmaceuticals
RIGL
$680M
| $19.4M | 0.02% |
501,016
+808
| +0.2% | +$30.8K |
|
596
Green Dot
GDOT
$753M
| $19.4M | 0.02% |
322,455
+310,435
| +2,583% | +$18.2M |
|
|
MDCO
597
DELISTED
Medicines Co
MDCO
| $19.4M | 0.02% |
708,834
-4,893
| -0.7% | -$151K |
|
598
Lamb Weston
LW
$6.82B
| $19.4M | 0.02% |
342,933
+6,558
| +2% | +$346K |
|
|
DOOR
599
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $19.3M | 0.02% |
259,780
+12,702
| +5% | +$887K |
|
600
CNO Financial Group
CNO
$4.97B
| $19.2M | 0.02% |
777,879
-94,903
| -11% | -$2.32M |
|
Similar funds
TA
TCIM
HFS
SBAM
BB
SA
WF
BCPEM
OppenheimerFunds's Q4 2017 Portfolio in Review
As of Q4 2017, OppenheimerFunds held 1,933 positions worth $82.8B, up 1.8% from $81.4B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
OppenheimerFunds's Q4 2017 filing shows 90 new, 882 increased, 857 reduced and 96 closed positions. Its largest new stake was Nebius Group N.V.: 5,110,710 shares worth $167M. The largest sale was Nektar Therapeutics, an estimated $401M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Energy.
- OppenheimerFunds's largest Q4 2017 buy was Nebius Group N.V.: 5,110,710 shares worth $167M.
- OppenheimerFunds added most to eBay in Q4 2017, an estimated $366M increase.
- OppenheimerFunds's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $401M.
- OppenheimerFunds fully exited NetEase in Q4 2017, selling an estimated $181M.
- OppenheimerFunds's ten largest holdings make up 16% of its $82.8B portfolio in Q4 2017.
- OppenheimerFunds opened 90 new positions and closed 96 in Q4 2017.
- OppenheimerFunds's portfolio value rose 1.8% quarter-over-quarter to $82.8B.
Based on OppenheimerFunds's 13F filing for Q4 2017, filed 12 Feb 2018.